Edition:
United Kingdom

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

601.90INR
23 Feb 2018
Change (% chg)

Rs15.05 (+2.56%)
Prev Close
Rs586.85
Open
Rs589.00
Day's High
Rs612.00
Day's Low
Rs588.05
Volume
5,799,249
Avg. Vol
2,350,495
52-wk High
Rs809.45
52-wk Low
Rs503.05

Select another date:

Wed, Feb 7 2018

BRIEF-Aurobindo Pharma Says Approved Dividend Of 1 Rupee Per Share

* SAYS APPROVED SECOND INTERIM DIVIDEND OF 1 RUPEE PER SHARE Source text for Eikon: Further company coverage:

Aurobindo Pharma Q3 profit up about 3 pct, misses estimates

Feb 7 Aurobindo Pharma Ltd, India's third largest drugmaker by revenue, posted an about 3 percent rise in quarterly profit on Wednesday, but missed analysts' estimates.

BRIEF-India's Aurobindo Pharma Dec-Qtr Consol Net Profit Rises About 3 Pct

* DEC QUARTER CONSOL NET PROFIT 5.95 BILLION RUPEES VERSUS 5.79 BILLION RUPEES LAST YEAR

BRIEF-Aurobindo Pharma Gets U.S. FDA Approval For Fondaparinux Sodium Injection

* SAYS GETS U.S. FDA APPROVAL FOR FONDAPARINUX SODIUM INJECTION Source text - http://bit.ly/2pK1kNR Further company coverage:

BRIEF-Aurobindo Pharma Says News On Co Being Frontrunner to Buy Orchid Pharma "Factually Incorrect"

* AUROBINDO PHARMA CLARIFIES ON NEWS ITEM, "AUROBINDO, DR REDDY'S LABORATORIES FRONTRUNNERS TO BUY OUT BANKRUPT ORCHID PHARMA"

Aurobindo Pharma Q2 profit rises 29 pct, beats estimates

Nov 9 India's Aurobindo Pharma Ltd posted a better-than-expected 29 percent rise in quarterly profit on Thursday, helped by higher sales at its formulations business in the United States.

BRIEF-Aurobindo Pharma gets U.S. FDA nod for esomeprazole magnesium DR capsules OTC

* Says ‍received final approval from U.S. FDA to manufacture esomeprazole magnesium delayed-release capsules OTC, 20mg​

Select another date: